Jan Borén, Alberico L. Catapano, Philippe Moulin, Carlos A. Aguilar-Salinas, Anne Tybjærg-Hansen, Sander Kersten, Lale Tokgozoglu, Maurizio Averna, Chris J. Packard, Daniel Gaudet, Henry N. Ginsberg, Brian A. Ference, Gary F. Lewis, Bart Staels, Jane K Stock, Alan T. Remaley, Børge G. Nordestgaard, Alice H. Lichtenstein, M. John Chapman, Robert A. Hegele, Erik S.G. Stroes, Marja-Riitta Taskinen, Columbia University [New York], University of Glasgow, Service d'Endocrinologie, Métabolisme et Prévention des Maladies Cardio-vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM), University of Gothenburg (GU), Sahlgrenska University Hospital [Gothenburg], Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán - National Institute of Medical Science and Nutrition Salvador Zubiran [Mexico], Tecnológico de Monterrey (ITESM), Università degli studi di Palermo - University of Palermo, University of Cambridge [UK] (CAM), Université de Montréal (UdeM), Schulich School of Medicine and Dentistry, University of Western Ontario (UWO), Wageningen University and Research [Wageningen] (WUR), University of Toronto, Tufts University School of Medicine [Boston], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Copenhagen University Hospital, University of Copenhagen = Københavns Universitet (UCPH), National Institutes of Health [Bethesda] (NIH), Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires (RNMCD - U1011), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Hacettepe University = Hacettepe Üniversitesi, Rigshospitalet [Copenhagen], Herlev and Gentofte Hospital, European Atherosclerosis Society [Göteborg, Sweden] (EAS), Università degli Studi di Milano = University of Milan (UNIMI), IRCCS Multimedica, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Gestionnaire, HAL Sorbonne Université 5, Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], University of Copenhagen = Københavns Universitet (KU), University of Helsinki, Università degli Studi di Milano [Milano] (UNIMI), Ginsberg, Henry N, Packard, Chris J, Chapman, M John, Borén, Jan, Aguilar-Salinas, Carlos A, Averna, Maurizio, Ference, Brian A, Gaudet, Daniel, Hegele, Robert A, Kersten, Sander, Lewis, Gary F, Lichtenstein, Alice H, Moulin, Philippe, Nordestgaard, Børge G, Remaley, Alan T, Staels, Bart, Stroes, Erik S G, Taskinen, Marja-Riitta, Tokgözoğlu, Lale S, Tybjaerg-Hansen, Anne, Stock, Jane K, Catapano, Alberico L, Clinicum, Marja-Riitta Taskinen Research Group, CAMM - Research Program for Clinical and Molecular Metabolism, HUS Helsinki and Uusimaa Hospital District, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 (RNMCD)
Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD). Key points are (i) a working definition of normo- and hypertriglyceridaemic states and their relation to risk of ASCVD, (ii) a conceptual framework for the generation of remnants due to dysregulation of TRL production, lipolysis, and remodelling, as well as clearance of remnant lipoproteins from the circulation, (iii) the pleiotropic proatherogenic actions of TRL and remnants at the arterial wall, (iv) challenges in defining, quantitating, and assessing the atherogenic properties of remnant particles, and (v) exploration of the relative atherogenicity of TRL and remnants compared to LDL. Assessment of these issues provides a foundation for evaluating approaches to effectively reduce levels of TRL and remnants by targeting either production, lipolysis, or hepatic clearance, or a combination of these mechanisms. This consensus statement updates current understanding in an integrated manner, thereby providing a platform for new therapeutic paradigms targeting TRL and their remnants, with the aim of reducing the risk of ASCVD., Graphical Abstract Formation of triglyceride-rich lipoprotein remnants and their role in atherogenesis. Metabolic scheme for the generation and clearance of triglyceride-rich lipoprotein remnant particles (A). In hypertriglyceridaemia, overproduction and inefficient lipolysis of both very low-density lipoprotein and chylomicrons lead to increased remnant formation. Triglyceride-rich lipoprotein remnants contribute to the initiation and progression of atherosclerotic lesions (B). Particle retention in the subendothelial space is followed by inflammation, cholesterol deposition, and macrophage foam cell formation.